Clinical efficacy and safety analysis of olanzapine in the treatment of mental disorders associated with brain organic diseases
10.3760/cma.j.issn.1008-6315.2017.12.009
- VernacularTitle:奥氮平治疗脑器质性疾病所致精神障碍的临床效果与安全性分析
- Author:
Ruixia ZHANG
1
;
Bing WU
Author Information
1. 内蒙古国际蒙医医院神经内科
- Keywords:
Olanzapine;
Brain Organic Mental Disorder;
Clinical Efficacy;
Safety
- From:
Clinical Medicine of China
2017;33(12):1093-1096
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of olanzapine in the treatment of mental disorders caused by brain organic diseases.Methods Eighty-one patients with mental disorder caused by brain organic disease were enrolled in the study and randomly divided into the control group(39 cases)and the experimental group(42 cases).The control group was treated with risperidone tablets and the experimental group was treated with olanzapine tablets,the patients in the two groups were treated for 4 weeks.After 4 weeks, the clinical efficacy,the scores of BPRS and the adverse reactions in the treatment were observed.Results The total efficiency of the control group 66.7%(26/39),the total efficiency of experimental group was 92.8%(39/42),there was significant difference in total efficiency between the two groups(χ2=7.889,P<0.05).Before the treatment,BRPS scores in the two groups were(51.42±6.38)points and(50.32±7.15)points,respectively, After 4 weeks of treatment,BRPS scores were(39.21 ± 7.43)points and(30.10 ± 3.88)points in the two groups,the differences in BPRS score in the two groups before treatment and at 4 weeks after treatment were statistically significant(control group: t=7.845,P=0.003,experimental group: t=8.321,P=0.002),there was significant difference between the control group and the experimental group in BPRS score(t=6.773,P=0.003).The incidence rate of body mass increase in the experimental group was 40.5%(17/42),significantly higher than that of the control group(15.4%)(6/39),the difference was statistically significant(χ2=6.576,P<0.05),while the incidence rates of myotonia and tremor adverse reaction were 16.7%(7/42)and 19.0%(8/42),significantly lower than those in the control group 35.9%(14/39)and 38.5%(15/39),the differences were statistically significant(myotonia:χ2=5.187,P<0.05;tremor; χ2=4.433,P<0.05).Adverse drug reactions can be effectively alleviated after symptomatic treatment.Conclusion Olanzapine has good clinical efficacy and safety and low adverse reactions in the treatment of mental disorders caused by organic brain disease.
